MILAN, Sept. 8, 2025 /PRNewswire/ — Newronika, a pioneer in adaptive deep brain stimulation technology (AlphaDBS™) is proud to announce the appointment of Mr. Keith Carlton as its new Executive Chairman, effective immediately.
Mr. Carlton brings extensive executive leadership experience in the medical device and neuromodulation sectors. Throughout his career, he has driven innovation, strategic growth, and operational excellence at the highest levels of industry – making him an ideal leader as Newronika embarks on its next phase of global expansion.
“We are honored to welcome Keith as our Executive Chairman,” said Lorenzo Rossi, PhD, Co-Founder and CEO of Newronika. “His strategic vision, coupled with a distinguished record of scaling innovative medical technology companies, will be pivotal as we advance the clinical validation and to the commercialization of AlphaDBS, our proprietary adaptive deep brain stimulation system. This innovative platform is designed to deliver precision therapy that enhances symptom relief and minimizes side effects for patients with Parkinson’s disease, while strengthening Newronika’s presence and impact worldwide.”
Carlo Sanfilippo, Senior Investment Manager at Indaco Venture Partners and member of Newronika Board, added, “We give Keith a warm welcome and are confident he has the required leadership and depth of experience in guiding the company through its next stage of growth.”
“It’s a privilege to join Newronika at such a transformative point in its journey,” added Mr. Carlton. “The company’s pioneering adaptive DBS technology holds the potential to redefine the standard of care for Parkinson’s disease and other neurological disorders. I look forward to collaborating with the Board and our talented team to accelerate innovation, broaden patient access, and deliver meaningful impact on a global scale with an initial key priority to support the successful launch of the Phase III U.S. Pivotal trial.”
Mr. Carlton’s appointment strengthens Newronika’s leadership foundation as the company continues to build upon recent milestones – including the CE Mark approval for AlphaDBS, U.S. FDA IDE clearance and the successful closing of a €13.6 million Series B financing round – further reinforcing its commitment to driving a paradigm shift in neuromodulation therapy globally.
About Newronika SpA
Newronika, a spin-off of Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico and the University of Milan, is transforming deep brain stimulation through adaptive technology that uses real-time neurophysiological feedback to optimize therapy. Headquartered in Milan, Italy, Newronika is dedicated to advancing adaptive DBS, with regulatory approvals and clinical initiatives underway in Europe, the U.S., and beyond.
Media Contact: Lorenzo Rossi, PhD, Co-founder & CEO
Mail: Lorenzo Rossi [email protected]
Newronika SpA
Website: www.newronika.com
Logo: https://mma.prnewswire.com/media/2612569/5150136/Newronika_Logo.jpg
